Engineered immune cells take aim at Hard-to-Treat brain tumors
NCT ID NCT04214392
First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 4 times
Summary
This early-stage trial tests a new type of CAR T-cell therapy designed to target a protein called MMP2 found on glioblastoma cells. The treatment uses a scorpion toxin fragment (chlorotoxin) to help the immune cells find and attack the tumor. Nineteen patients with recurrent or progressive glioblastoma will receive the cells directly into the brain to assess safety and the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Chlorotoxin-targeted CAR T-cells
- What this could lead to
- If successful, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few effective therapies.
- What could go wrong
- This is a very early phase 1 trial with only 19 participants, so safety and dosing are still being determined. The treatment may not shrink tumors or improve survival, and there are risks like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a modified herpes virus fight recurrent brain tumors?
- Can a new pill take on brain cancer?
- Can a special MRI reveal hidden brain tumors and guide a stronger radiation strike?
- Radioactive beads take aim at brain tumours
- Two-Drug combo aims to outsmart recurrent brain tumors